Log in

Intec Pharma Stock Price, News & Analysis (NASDAQ:NTEC)

$0.74
+0.01 (+1.37 %)
(As of 10/24/2019 01:30 AM ET)
Today's Range
$0.73
Now: $0.74
$0.76
50-Day Range
$0.63
MA: $0.83
$1.38
52-Week Range
$0.41
Now: $0.74
$9.25
Volume220,175 shs
Average Volume994,227 shs
Market Capitalization$24.29 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.01
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.63 per share

Profitability

Net Income$-43,540,000.00

Miscellaneous

Employees70
Market Cap$24.29 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.


Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its earnings results on Friday, August, 9th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.02. View Intec Pharma's Earnings History.

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Intec Pharma.

What price target have analysts set for NTEC?

5 Wall Street analysts have issued 1-year target prices for Intec Pharma's shares. Their predictions range from $1.00 to $16.00. On average, they anticipate Intec Pharma's share price to reach $11.80 in the next twelve months. This suggests a possible upside of 1,494.6% from the stock's current price. View Analyst Price Targets for Intec Pharma.

What is the consensus analysts' recommendation for Intec Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intec Pharma.

What are Wall Street analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:
  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (10/16/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are modeling mid-’19 cash is sufficient to fund operations till late 2020. While we appreciate Accordion Pill’s controlled-release abilities and still find AP-CBD/THC’s PK results vs. Sativex as impressive (290-330% and 25-50% higher exposures of CBD and THC, respectively, than Sativex), we have little insight into how the AP-Novartis Phase 1 may come out. Intec’s collaboration on an undisclosed compound was announced. Intec reported it successfully developed an a proprietary Novartis compound that met the prerequisite in vitro specifications. In 1Q’19 a human PK began, with the expectation for completion of the study and the results this summer, with Novartis making a go/no-go decision on a Phase 2 this fall." (8/12/2019)
  • 3. Maxim Group analysts commented, "Intec announced the presentation of the results from its PK study on AP-CD/ LD (Accordion Pill – Carbidopa/Levodopa) in Parkinson’s disease (PD) at the XXIV Related Disorders. The data was originally reported on 2/19 (see note, LINK), however, additional detail was provided in the presentation." (6/20/2019)

Has Intec Pharma been receiving favorable news coverage?

News stories about NTEC stock have trended neutral this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intec Pharma earned a news impact score of 0.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Intec Pharma.

Are investors shorting Intec Pharma?

Intec Pharma saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,070,000 shares, an increase of 120.5% from the August 30th total of 485,300 shares. Based on an average daily trading volume, of 2,550,000 shares, the short-interest ratio is currently 0.4 days. Currently, 3.9% of the company's stock are sold short. View Intec Pharma's Current Options Chain.

Who are some of Intec Pharma's key competitors?

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Intel (INTC), Verastem (VSTM), AbbVie (ABBV), Aurora Cannabis (ACB), Netflix (NFLX), SCYNEXIS (SCYX) and Zynerba Pharmaceuticals (ZYNE).

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)
  • Mr. Nir Sassi, Chief Financial Officer (Age 43)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)
  • Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)
  • Dr. R. Michael Gendreau, Chief Medical Officer (Age 63)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $0.74.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $24.29 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.View Additional Information About Intec Pharma.

What is Intec Pharma's official website?

The official website for Intec Pharma is http://www.intecpharma.com/.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]


MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel